• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Brand Quest
• The New Manager
• BL Club
• Smartbuy
• Books
• Gallery

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth
• Events 2007

Group Sites

• The Hindu
• The Hindu ePaper
• Business Line
• Business Line ePaper
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

Chennai, Sept. 16 Orchid Chemicals and Pharmaceuticals Ltd on Wednesday announced that it has received approvals from the US Food and Drug Administration for its anti-infection drug Piperacillin-Tazobactam, in injectible form.

These approvals cover Orchid’s generic equivalents in 2.25 g, 3.375 g and 4.5 g vial as well as 40.5 g (pharmacy bulk package) dosage forms and strengths.

The US FDA determined that Orchid is a ‘first applicant’ for the products and granted 180-day generic drug exclusivity. Orchid will launch these products in marketing and distribution partnership with Apotex in the US.

More Stories on : Regulatory Bodies & Rulings | Pharmaceuticals | Stocks

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Copyright © 2009, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line